Lupus Clinical Trials in Beijing
21 recruitingBeijing, China
Showing 1–20 of 21 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
UCB Biopharma SRL450 enrolled225 locationsNCT06617325
Recruiting
Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Rheumatoid ArthritisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathies
AstraZeneca72 enrolled35 locationsNCT06916806
Recruiting
Phase 1
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Rheumatoid ArthritisHealthySystemic Lupus Erythematosus
Eli Lilly and Company63 enrolled7 locationsNCT07276958
Recruiting
Phase 2
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Lupus Nephritis
Novartis Pharmaceuticals240 enrolled103 locationsNCT05268289
Recruiting
Phase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Systemic Lupus Erythematosus
AstraZeneca100 enrolled97 locationsNCT05835310
Recruiting
Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
Lupus Nephritis
Novartis Pharmaceuticals462 enrolled188 locationsNCT05126277
Recruiting
Phase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Novartis Pharmaceuticals550 enrolled127 locationsNCT06133972
Recruiting
Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
AstraZeneca302 enrolled272 locationsNCT06015737
Recruiting
Phase 3
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Lupus Nephritis
Novartis Pharmaceuticals315 enrolled25 locationsNCT06711887
Recruiting
Phase 1
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Hangzhou Qihan Biotech Co., Ltd.18 enrolled3 locationsNCT07444307
Recruiting
Phase 1
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Rheumatoid ArthritisSystemic Lupus Erythematosus
AstraZeneca48 enrolled19 locationsNCT07201558
Recruiting
Phase 1
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
Lupus Nephritis (LN)Membranous Nephropathy
Shanghai Henlius Biotech24 enrolled17 locationsNCT07038382
Recruiting
Phase 1
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Candid Therapeutics47 enrolled1 locationNCT07215663
Recruiting
Phase 1Phase 2
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Sjogren SyndromeSystemic Lupus ErthematosusSystemic Sclerosis (SSc)+3 more
Peking University Third Hospital9 enrolled1 locationNCT06828042
Recruiting
Phase 1
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Idiopathic Inflammatory Myopathy (IIM)+1 more
Beijing GoBroad Hospital44 enrolled2 locationsNCT06980597
Recruiting
Phase 1
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
Systemic Lupus Erythematosus
HC Biopharma Inc.38 enrolled3 locationsNCT06657703
Recruiting
Phase 1Phase 2
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
System Lupus Erythematosus
Sinocelltech Ltd.168 enrolled14 locationsNCT06841042
Recruiting
Phase 4
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
Systemic Lupus ErythematosusLupus Nephritis
Chinese SLE Treatment And Research Group220 enrolled1 locationNCT05916781
Recruiting
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
Lupus Nephritis
Chinese SLE Treatment And Research Group100 enrolled1 locationNCT06167174